Synageva makes public spectacle with $60 million stock offer after Trimeris merger
This article was originally published in Scrip
Executive Summary
Synageva BioPharma, a Lexington, Massachussetts-based company focused on rare disorders and unmet medical needs is looking to raise $60 million in an offering of common stock to advance some of its programmes in enzyme replacement therapies for rare diseases.